[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.173.36. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Neurological Review
January 2009

A Renaissance for Antisense Oligonucleotide Drugs in Neurology: Exon Skipping Breaks New Ground

Author Affiliations

Author Affiliations:Research Center for Genetic Medicine, Children's National Medical Center, Washington, DC (Drs Yokota, Partridge, and Hoffman); Department of Molecular Medicine, National Institutes for Neuroscience, Tokyo, Japan (Drs Takeda and Nakamura); and McColl-Lockwood Laboratory for Muscular Dystrophy Research, Neuromuscular/ALS Center, Carolinas Medical Center, Charlotte, North Carolina (Dr Lu).

 

DAVID E.PLEASUREMD

Arch Neurol. 2009;66(1):32-38. doi:10.1001/archneurol.2008.540
Abstract

Antisense oligonucleotides are short nucleic acid sequences designed for use as small-molecule drugs. They recognize and bind to specific messenger RNA (mRNA) or pre-mRNA sequences to create small double-stranded regions of the target mRNA that alter mRNA splicing patterns or inhibit protein translation. Antisense approaches have been actively pursued as a form of molecular medicine for more than 20 years, but only one has been translated to a marketed drug (intraocular human immunodeficiency virus treatment). Two recent advances foreshadow a change in clinical applications of antisense strategies. First is the development of synthetic DNA analogues that show outstanding stability and sequence specificity yet little or no binding to modulator proteins. Second is the publication of impressive preclinical and clinical data using antisense in an exon-skipping strategy to increase dystrophin production in Duchenne muscular dystrophy. As long-standing barriers are successfully circumvented, attention turns toward scale-up of production, long-term toxicity studies, and the challenges to traditional drug regulatory attitudes presented by tightly targeted sequence-specific drugs.

×